<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194077</url>
  </required_header>
  <id_info>
    <org_study_id>Children with Mania</org_study_id>
    <nct_id>NCT00194077</nct_id>
  </id_info>
  <brief_title>Study of Aripiprazole (Abilify) in Children With Symptoms of Mania</brief_title>
  <official_title>Aripiprazole in Children With Symptoms of Mania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the safety and effectiveness of aripiprazole
      (abilify) in children with bipolar disorder and to examine whether or not patients that
      respond to initial mood stabilization benefit from continued pharmacotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This outpatient study will be conducted in 3 phases. Phase 1: Patients meeting entry criteria
      will be treated with open label aripiprazole (APZ) in order to achieve therapeutic doses of
      this agent. The primary objective of this phase is to stabilize the patient's mood prior to
      randomization in phase 2. Adjunctive treatment of attention-deficit hyperactivity disorder
      (ADHD) will be permitted during this phase after week 6 of phase 1. In order to be entered
      into Phase 2, patients must be clinically stable based on a priori criteria (see below). The
      maximum allowable duration of Phase 1 will be 16 weeks. Only patients who have achieved
      syndromal remission (not just improvement) will be eligible for randomization into phase 2.

      Phase 2: Patients that achieve syndromal remission during Phase 1 will be randomized in a
      double-blind fashion to receive either ongoing APZ therapy or placebo therapy during Phase 2.
      Patients who are receiving co-administration of ADHD pharmacotherapy may continue with this
      during Phase 2. Patients will have an equal chance of being assigned to each of the 2
      treatment arms. Randomization strata will be based on whether or not the subject is receiving
      ADHD pharmacotherapy and whether or not the subject is suffering from Bipolar 1 or 2
      disorders. The maximum length of time a patient may remain in phase 2 will be 72 weeks.
      Youths who develop a major depressive episode, a manic, or mixed episode, or youths for whom
      continued enrollment in this phase of study is contraindicated (as determined by the patient,
      guardian, research team or study physician), will be withdrawn from phase 2. Youths who
      withdraw from phase 2 may enter Phase 3. Reason for removal from phase 2 will be documented.
      For those youths who successfully complete 72 weeks of participation in phase 2, trial
      participation will be ended. Those patients who complete phase 2 will receive follow up
      clinical care either at University Hospitals-Cleveland (UHC) or with a community-based
      physician.

      Phase 3: For youths who are withdrawn during phase 2, 8-weeks of open-label treatment with
      APZ will be available
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in Weeks to Discontinuation</measure>
    <time_frame>up to 72 weeks</time_frame>
    <description>Time in weeks to discontinuation due to any reason, including mood event, adverse event, or other.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase I and Phase III are open label Abilify phases where all subjects receive active Abilify</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>in Phase 2 subjects are randomized to either placebo or abilify for up to 72 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subjects in phase 2 will be randomized to active abilify or placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients ages 4-9 years (inclusive)

          -  Patients who are anticipated to have a Young Mania Rating Scale (Young et al. 1978) of
             15 or higher at baseline

          -  Meet DSM-IV criteria for bipolar disorder type 1 or 2, cyclothymia, or bipolar
             disorder not otherwise specified (BP NOS) based on the results of both a
             semi-structured diagnostic research assessment (K-SADS-PL supplemented with mood
             disorder sections from the WASH-U K-SADS) (Geller et al., 2001; Kaufman et al., 1997)
             and a clinical interview with a child and adolescent psychiatrist.

        Exclusion Criteria:

          -  Patients who have a history of intolerance to APZ at doses of 0.1mg/kg/day

          -  Patients who have experienced a manic episode with a documented APZ dose as
             monotherapy treatment of 0.2 mg/kg/day

          -  Patients with an active neurological/medical disorder for which treatment with APZ
             would be contraindicated

          -  Patients with clinical evidence of autistic disorder, Asperger's disorder, Rett's
             syndrome or other pervasive developmental disorders

          -  Patients with clinical evidence of mental retardation

          -  Patients who are known to be allergic or hypersensitive to aripiprazole

          -  Patients who are unable to swallow pills/capsules

          -  Patients for whom the need for hospitalization during the course of the study appears
             likely

          -  Patients who have a general medical or neurological condition (including clinically
             significant abnormalities on screening laboratories) that may be considered to be the
             etiology of the patient's mood disorder

          -  Patients who have a general medical or neurological condition for which treatment with
             an atypical antipsychotic would be contraindicated (e.g. tardive dyskinesia)

          -  Patients who have a general medical or neurological condition that could interfere
             with the interpretation of clinical response to APZ treatment

          -  Patients taking psychotropic agents (other than psychostimulants) within one week of
             baseline (2 weeks for fluoxetine; 3 days for psychostimulants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L Findling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Findling RL, Youngstrom EA, McNamara NK, Stansbrey RJ, Wynbrandt JL, Adegbite C, Rowles BM, Demeter CA, Frazier TW, Calabrese JR. Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry. 2012 Jan;73(1):57-63. doi: 10.4088/JCP.11m07104. Epub 2011 Nov 29.</citation>
    <PMID>22152402</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>June 26, 2013</results_first_submitted>
  <results_first_submitted_qc>November 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2013</results_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Robert L Findling, MD</investigator_full_name>
    <investigator_title>Director, Division of Child and Adolescent Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment University Hospitals, Case Medical Center</recruitment_details>
      <pre_assignment_details>Open stabilization was initiated with aripiprazole at~0.1mg/kg upon phase 1, open stabilization entry, n+96. Of these, 60 subjects met priori response to advance to phase 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole</title>
          <description>Random assignment with titrated dosing</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Randomized assignment to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6">Lack of efficacy:
Hypomania n=12 Cycling n=5 Mixed state=4 Mania n=1</participants>
                <participants group_id="P2" count="0">Lack of efficacy:
hypomania n=17 Cycling n=6 Mania n=5 Mixed state n=1 Concern regarding tx n=1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study nonadherence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No differences.</population>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole</title>
          <description>Abilify (Children with Symptoms of Mania Study)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (Children with Symptoms of Mania Study)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time in Weeks to Discontinuation</title>
        <description>Time in weeks to discontinuation due to any reason, including mood event, adverse event, or other.</description>
        <time_frame>up to 72 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Aripiprazole dosing dependent upon response</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dosing to mirror active treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Weeks to Discontinuation</title>
          <description>Time in weeks to discontinuation due to any reason, including mood event, adverse event, or other.</description>
          <units>time in weeks to discontinuation</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.93" lower_limit="15.08" upper_limit="36.78"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.89" upper_limit="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole</title>
          <description>Abilify (Children With Symptoms of Mania Study)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (Children With Symptoms of Mania Study)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No deaths occured during this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Findling, MD,MBA Director, Child and Adolescent Psychiatry</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-614-3225</phone>
      <email>rfindli1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

